285 related articles for article (PubMed ID: 32896101)
21. A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-10
Tembhare PR; Subramanian Pg PG; Ghogale S; Chatterjee G; Patkar NV; Gupta A; Shukla R; Badrinath Y; Deshpande N; Narula G; Rodrigues P; Girase K; Dhaliwal D; Prasad M; Shetty D; Banavali S; Gujral S
Cytometry B Clin Cytom; 2020 Jan; 98(1):57-67. PubMed ID: 31197916
[TBL] [Abstract][Full Text] [Related]
22. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
[TBL] [Abstract][Full Text] [Related]
23. Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
Mikhailova E; Semchenkova A; Illarionova O; Kashpor S; Brilliantova V; Zakharova E; Zerkalenkova E; Zangrando A; Bocharova N; Shelikhova L; Diakonova Y; Zhogov V; Khismatullina R; Molostova O; Buldini B; Raykina E; Larin S; Olshanskaya Y; Miakova N; Novichkova G; Maschan M; Popov AM
Br J Haematol; 2021 May; 193(3):602-612. PubMed ID: 33715150
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
DiGiuseppe JA; Fuller SG; Borowitz MJ
Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia.
Sędek Ł; Theunissen P; Sobral da Costa E; van der Sluijs-Gelling A; Mejstrikova E; Gaipa G; Sonsala A; Twardoch M; Oliveira E; Novakova M; Buracchi C; van Dongen JJM; Orfao A; van der Velden VHJ; Szczepański T;
J Immunol Methods; 2019 Dec; 475():112429. PubMed ID: 29530508
[TBL] [Abstract][Full Text] [Related]
26. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: a study of five cases controlled by genetic methods.
Dworzak MN; Stolz F; Fröschl G; Printz D; Henn T; Fischer S; Fleischer C; Haas OA; Fritsch G; Gadner H; Panzer-Grümayer ER
Exp Hematol; 1999 Apr; 27(4):673-81. PubMed ID: 10210325
[TBL] [Abstract][Full Text] [Related]
27. Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia.
Tsitsikov E; Harris MH; Silverman LB; Sallan SE; Weinberg OK
Int J Lab Hematol; 2018 Jun; 40(3):343-351. PubMed ID: 29500862
[TBL] [Abstract][Full Text] [Related]
28. High frequency of heat shock protein 27 overexpression is a highly effective, high-coverage marker for minimal residual disease detection in children with B-cell acute lymphoblastic leukemia.
Chou SW; Su YH; Lu MY; Chang HH; Yang YL; Lin DT; Lin KH; Coustan-Smith E; Jou ST
Pediatr Blood Cancer; 2023 Jan; 70(1):e29990. PubMed ID: 36250996
[TBL] [Abstract][Full Text] [Related]
29. Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.
Baraka A; Sherief LM; Kamal NM; Shorbagy SE
Int J Hematol; 2017 Jun; 105(6):784-791. PubMed ID: 28324281
[TBL] [Abstract][Full Text] [Related]
30. Significance of CD34/CD123 expression in detection of minimal residual disease in B-ACUTE lymphoblastic leukemia in children.
Zeidan MA; Kamal HM; El Shabrawy DA; Esh AM; Sattar RH
Blood Cells Mol Dis; 2016 Jul; 59():113-8. PubMed ID: 27282579
[TBL] [Abstract][Full Text] [Related]
31. Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B-lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease.
Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Girase K; Verma S; Arolkar G; Dasgupta N; Narula G; Shetty D; Dhamne C; Moulik NR; Rajpal S; Patkar NV; Banavali S; Gujral S; Subramanian PG; Tembhare PR
Br J Haematol; 2022 Jan; 196(2):374-379. PubMed ID: 34476808
[TBL] [Abstract][Full Text] [Related]
32. [Application of effective antigen combinations in childhood B lineage acute lymphoblastic leukemia].
Liu Y; Tang JY; Xu C; Gu LJ; Xue HL; Chen J; Pan C; Dong L; Zhou M
Zhonghua Er Ke Za Zhi; 2009 May; 47(5):366-70. PubMed ID: 19573409
[TBL] [Abstract][Full Text] [Related]
33. CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment.
Buldini B; Varotto E; Maurer-Granofszky M; Gaipa G; Schumich A; Brüggemann M; Mejstrikova E; Cazzaniga G; Hrusak O; Szczepanowski M; Scarparo P; Zimmermann M; Strehl S; Schinnerl D; Zaliova M; Karawajew L; Bourquin JP; Feuerstein T; Cario G; Alten J; Möricke A; Biffi A; Parasole R; Fagioli F; Valsecchi MG; Biondi A; Locatelli F; Attarbaschi A; Schrappe M; Conter V; Basso G; Dworzak MN
Blood; 2024 Apr; 143(17):1738-1751. PubMed ID: 38215390
[TBL] [Abstract][Full Text] [Related]
34. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection.
Weir EG; Cowan K; LeBeau P; Borowitz MJ
Leukemia; 1999 Apr; 13(4):558-67. PubMed ID: 10214862
[TBL] [Abstract][Full Text] [Related]
35. Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells.
Gaipa G; Basso G; Aliprandi S; Migliavacca M; Vallinoto C; Maglia O; Faini A; Veltroni M; Husak D; Schumich A; Ratei R; Biondi A; Dworzak MN;
Cytometry B Clin Cytom; 2008 May; 74(3):150-5. PubMed ID: 18271020
[TBL] [Abstract][Full Text] [Related]
36. Deciphering stage 0 hematogones by flow cytometry in follow-up bone marrow samples of pediatric B-Acute lymphoblastic leukemia cases: A potential mimicker of residual disease after anti CD19 therapy.
Ramalingam TR; Vaidhyanathan L; Muthu A; Swaminathan VV; Uppuluri R; Raj R
Cytometry B Clin Cytom; 2024 Mar; 106(2):92-98. PubMed ID: 38243626
[TBL] [Abstract][Full Text] [Related]
37. The significance of peripheral blood minimal residual disease to predict early disease response in patients with B-cell acute lymphoblastic leukemia.
Setiadi A; Owen D; Tsang A; Milner R; Vercauteren S
Int J Lab Hematol; 2016 Oct; 38(5):527-34. PubMed ID: 27339737
[TBL] [Abstract][Full Text] [Related]
38. B-lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targeting.
Mikhailova E; Itov A; Zerkalenkova E; Roumiantseva J; Olshanskaya Y; Karachunskiy A; Novichkova G; Maschan M; Popov A
Cytometry B Clin Cytom; 2022 Sep; 102(5):353-359. PubMed ID: 35796438
[TBL] [Abstract][Full Text] [Related]
39. Application and prognostic relevance of CD34 detection in immunophenotyping of pediatric acute B lymphoblastic leukemia.
Zha W; Yuan Y; Yang T; Zhu LJ; Kong WY; Zhuo JJ
Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3384-3390. PubMed ID: 38766795
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of immunophenotypic markers in pediatric T-cell acute lymphoblastic leukemia.
Sidhom I; Shaaban K; Soliman S; Ezzat S; El-Anwar W; Hamdy N; Yassin D; Salem S; Hassanein H; Mansour MT
J Egypt Natl Canc Inst; 2008 Jun; 20(2):111-20. PubMed ID: 20029466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
